Lack of MHC restriction enables applicability to patients expressing surface TAAs regardless of MHC allele expression.Efficient depletion of hematologic cancer.Off-target ‘bystander’ killing of antigen-negative tumor cells. Here, HLA-C is linked to hematopoietic and lymphoid cell neoplasm.